Compass Therapeutics CAO Neil Lerner buys $18,400 in company shares By Investing.com
Neil Lerner, Chief Accounting Officer of Compass Therapeutics (NASDAQ:CMPX), purchased 20,000 shares of company stock for $18,400 at $0.92 per share. This transaction occurred on October 1, 2026, and increases his direct holdings to 420,000 shares, which includes unvested restricted stock units. The purchase happened as the stock is trading near its 52-week low, and comes amidst varying analyst outlooks following an FDA recommendation for an additional trial for tovecimig.
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com
This article reports on a Form 4 filing for Compass Therapeutics, Inc. as of October 2. The filing is presented without additional commentary or details in the brief news item. The stock symbol CMPX is mentioned with a -4.88% change.
Form 4 Compass Therapeutics, Inc. For: 2 October By Investing.com
This article reports on a Form 4 filing for Compass Therapeutics, Inc. (CMPX) on October 2. Form 4 filings are used to disclose transactions by company insiders. The article includes the stock symbol CMPX and its performance on the given day.
Compass Therapeutics Inc. (CMPX) Stock Price Target & Forecast
This article provides an analysis of Compass Therapeutics Inc. (CMPX) stock, including analyst ratings and financial forecasts. Based on 15 analysts, the average price target for CMPX is $5.909, suggesting a significant upside. The article also details EPS forecasts, with FY2026Q3 projected at -0.127.
Compass Therapeutics (CMPX) Insider Buy: Chief Accounting Officer Neil Lerner Purchases 2,500 Shares
Compass Therapeutics' Chief Accounting Officer, Neil Lerner, recently purchased 2,500 shares, increasing his total ownership to 400,000 shares. This transaction is part of a larger trend of insider buying at CMPX, with 3 buys and 0 sells over the past year, indicating a positive outlook from insiders. Additionally, GuruFocus data shows 4 gurus holding CMPX shares, with most adding to their positions, further suggesting confidence in the clinical-stage biopharmaceutical company despite the inherent risks of drug development.
After buying 2,500 shares, Compass Therapeutics (CMPX) accounting chief reports a 400,000-share position
Neil Lerner, Chief Accounting Officer at Compass Therapeutics (CMPX), purchased 2,500 common shares at $1.14 each on September 24, 2026. This transaction increased his direct holdings to 400,000 shares, which includes 62,500 unvested restricted stock units set to vest annually starting January 2, 2027. The filing indicates a neutral sentiment and highlights the insider's long-term position in the company.
Is Compass Therapeutics, Inc. (CMPX) the Healthcare Stocks Stock Everyone's About to Talk About?
Compass Therapeutics, Inc. (CMPX) is drawing market attention after the FDA recommended an additional survival study for its tovecimig biologics application in biliary tract cancer. The article highlights that the market will focus on the company's execution, customer response, and how sector conditions and competitive pressures affect its operations following this development. Investors are advised to look for consistent delivery and operational evidence in future disclosures rather than just the initial announcement.
Form 4 Compass Therapeutics, Inc. For: 25 September By Investing.com
This article reports on a Form 4 filing for Compass Therapeutics, Inc. (CMPX) on September 25, 2026. The Form 4 is a document filed with the SEC to disclose changes in beneficial ownership of securities by a company's insiders. The article provides no further details about the content of the filing or the transaction itself.
Compass Therapeutics Shares Drop After Downgrade From Wedbush
Compass Therapeutics (CMPX) shares experienced a nearly 7% decline on Wednesday following a downgrade from Wedbush. The article indicates that access to the full details of this report requires a premium subscription.
Compass Therapeutics stock downgraded at Wedbush (CMPX:NASDAQ)
Compass Therapeutics (CMPX) was downgraded to Neutral from Outperform by Wedbush after the FDA recommended an additional study for its lead asset, tovecimig. The cancer drug developer's stock continued to trade lower following this news. The biotech company is based in Boston, Massachusetts.
The FDA recommended a trial to show patients live longer. Compass says its current study is enough.
The FDA has recommended that Compass Therapeutics conduct an additional trial demonstrating overall survival benefit before submitting a Biologics License Application (BLA) for its drug, tovecimig, in advanced biliary tract cancer. Compass Therapeutics believes its current Phase 2/3 COMPANION-002 study, which showed significant improvements in objective response rate and progression-free survival, is sufficient for BLA submission, especially given the urgent unmet medical need. The company plans further engagement with the FDA to discuss the path forward, despite the initial unexpected feedback.
Wedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $5
Wedbush has downgraded Compass Therapeutics (CMPX) from Outperform to Neutral and significantly cut its price target from $5 to $1. This downgrade comes after the FDA recommended a new trial for Tovecimig in biliary tract cancer, causing the company's shares to drop. Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for various diseases.
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA has recommended an additional trial demonstrating a survival benefit for tovecimig in biliary tract cancer patients before a BLA submission. Despite this, Compass intends to proceed with BLA preparations, citing significant improvements in ORR and PFS from their COMPANION-002 study and the urgent unmet medical need. The company remains confident in tovecimig's potential, believing the existing data supports its clinical meaningfulness.
Compass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares Fall
Compass Therapeutics' shares dropped over 38% pre-bell after the company announced that the FDA recommended a new trial for Tovecimig in biliary tract cancer. The article implies that this news was perceived negatively by the market, leading to a significant stock price decline. Full details of the FDA's recommendations and the company's response are behind a paywall.
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA has recommended an additional trial to demonstrate a survival benefit for tovecimig in biliary tract cancer before a BLA submission. The company, however, believes that a new trial is not warranted given the positive data from the COMPANION-002 study and the urgent unmet medical need. Compass Therapeutics intends to continue engaging with the FDA while preparing its BLA submission, expressing confidence in tovecimig's clinically meaningful activity.
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Compass Therapeutics announced that the FDA recommended a survival benefit trial before a Biologics License Application (BLA) submission for tovecimig in biliary tract cancer (BTC). Despite this, Compass plans to further engage with the FDA and prepare a BLA, confident in the positive Phase 2/3 COMPANION-002 study results which showed significant improvements in objective response rate and progression-free survival. The company believes a new trial is not warranted given the urgent unmet medical need and existing data.
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts
Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average "Moderate Buy" rating from sixteen research firms, with an average 12-month price target of $11.77. Despite this bullish sentiment from analysts, the company's shares are trading down 0.4% at $2.25, and it reported a quarterly loss of $0.13 per share, missing consensus estimates. Institutional investors hold a significant 68.43% of CMPX shares, with several firms recently increasing their positions.
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6
Stifel has reiterated its Buy rating on Compass Therapeutics (CMPX.US) and maintained its target price of $6. This indicates the firm's continued confidence in the company's prospects.
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
This article highlights three promising penny stocks for investors' watchlists: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite varying financial statuses—from pre-revenue to strong growth—all three companies are presented with an overview of their operations, market capitalization, and key financial health indicators, emphasizing their potential for growth in a positive market trend.
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist
This article highlights three promising "penny stocks" with strong financial health: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite their status as penny stocks, the companies demonstrate potential for growth and value backed by solid fundamentals. The analysis details their financial performance, market capitalization, and future prospects based on recent earnings and analyst forecasts.
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate
This article assesses Compass Therapeutics' cash burn rate, concluding that despite a high burn rate relative to its market cap, the company has a substantial cash reserve that should last for over two years. The analysis suggests that while the burn rate is a factor, the current cash runway provides a significant buffer against immediate financial concerns.
Compass Therapeutics (CMPX) Short Interest & Short Float | Updated Aug 2026
As of July 31, 2026, Compass Therapeutics (CMPX) had a short interest of 39.87 million shares, representing 27.23% of its public float, marking a 1.47% increase from the prior report. The short interest ratio is 17.6 days to cover, indicating a significant amount of time short sellers would need to cover their positions. The article provides detailed historical short interest data for CMPX and explains key short interest metrics and how they compare to competitors.
State Street (CMPX holder) reports 9.95M Compass Therapeutics shares on Schedule 13G
State Street Corporation has reported a beneficial ownership of 9,953,653 shares of Compass Therapeutics Inc. common stock, which represents a 5.5% stake in the company as of June 30, 2026. The filing, a Schedule 13G, indicates that State Street holds shared voting power over 9,687,331 shares and shared dispositive power over all 9,953,653 shares through various investment management subsidiaries. This disclosure provides insight into State Street's passive investment in Compass Therapeutics.
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate
Compass Therapeutics (NASDAQ:CMPX) is not causing concern despite its cash burn rate. The company has a cash runway of 3.4 years, and analysts predict it will reach cash flow breakeven before exhausting its funds. Although cash burn increased by 18% last year, its market capitalization is sufficient to raise additional capital if needed without significant shareholder dilution.
Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to Strong Sell at Wall Street Zen
Wall Street Zen has downgraded Compass Therapeutics (NASDAQ:CMPX) from a "sell" to a "strong sell" rating, despite a broader analyst consensus of "Moderate Buy." The company reported a quarterly loss of $0.13 per share, missing analyst expectations, and its shares opened near their 52-week low. Institutional investors hold a significant stake, with several hedge funds recently increasing their positions in the immuno-oncology company.
Compass Therapeutics (NASDAQ:CMPX) Posts Earnings Results, Misses Expectations By $0.02 EPS
Compass Therapeutics (NASDAQ:CMPX) reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite the earnings miss, the stock rose to $2.15 in Friday trading, though it remains significantly below its 12-month high. Analysts maintain a "Moderate Buy" rating with an average price target of $11.77, and institutional investors hold a substantial portion of the company's shares.
Compass Therapeutics Inc. (CMPX) Stock News Today
This article provides current stock news for Compass Therapeutics Inc. (CMPX), including its recent stock performance, market capitalization, and a note about upcoming earnings. As of the close on August 7th, CMPX stock was up 8.04% at $2.150. The content highlights the company's financial data, ownership, and technical forecasts available on the TradingKey platform.
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com
The article reports on a Form 8K filing by Compass Therapeutics, Inc. for August 6th. The publication, from Investing.com, indicates the filing is publicly available for review. This brief announcement is situated within a broader financial news platform.
Compass Therapeutics, Inc. Stock 12‑Month Price Target Raised to $8.67, Implies 359% Upside
Compass Therapeutics, Inc. (CMPX) has seen its average 12-month stock price target raised to $8.67 from $8.50 by 12 analysts, with forecasts ranging from $4 to $24 per share. This new target suggests a potential upside of approximately 359% based on the Aug. 5 closing price. The consensus rating for CMPX remains a "Buy" from 15 analysts.
Compass Therapeutics, Inc. 2026: Revenue ($25.25M), Net income ($25.15M), EPS ($0.13) — 10-Q Summary
Compass Therapeutics, Inc. reported its 2026 quarterly results, showing increased comprehensive and net losses compared to the previous year, driven by advancements in multiple clinical programs and expanded pre-commercialization spending. Despite the losses, the company highlighted positive clinical milestones, pipeline progress with four advancing clinical candidates, and increased operational scale-up. Management anticipates existing cash resources will fund operations into 2028, with plans for future financing through equity, debt, or partnerships.
Compass Therapeutics (NASDAQ: CMPX) details Q2 loss and BTC trial gains
Compass Therapeutics (
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its second-quarter 2026 financial results, highlighting a cash position of $180 million expected to fund operations into 2028. The company is advancing several clinical-stage oncology programs, with key updates including anticipated FDA feedback on tovecimig data, ongoing enrollment for CTX-8371 and CTX-10726 cohort expansions, and the planned initiation of a Phase 2 study for CTX-471. The net loss for the quarter was $25.2 million, driven by increased R&D and G&A expenses.
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Compass Therapeutics reported its second quarter 2026 financial results and provided a corporate update, highlighting ongoing clinical trials for its antibody-based therapeutics. The company expects FDA feedback on tovecimig data this quarter, anticipating a BLA filing later this year, and is advancing other bispecific antibody candidates like CTX-8371 and CTX-10726 through their respective clinical phases. With $180 million in cash and marketable securities, Compass Therapeutics projects its operations to be funded into 2028.
Form 8K Compass Therapeutics, Inc. For: 6 August By Investing.com
This article announces that Compass Therapeutics, Inc. filed a Form 8K on August 6th. The filing is available through Investing.com, a financial markets platform. The news briefly mentions the company's stock symbol CMPX and its performance, but primarily serves as a notification about the SEC filing.
Compass Therapeutics Inc. (CMPX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Compass Therapeutics Inc. (CMPX), detailing its price momentum, support and resistance levels, and various technical indicators. The stock currently has a price momentum score of 4.33, trading between resistance at $2.28 and support at $1.77. While some indicators suggest a 'Sell' signal, the overall signal based on moving averages and other technical indicators is 'Neutral'.
Compass Therapeutics, Inc. $CMPX Shares Sold by Rock Springs Capital Management LP
Rock Springs Capital Management LP significantly reduced its stake in Compass Therapeutics (NASDAQ:CMPX) by 15.8% in the first quarter, selling 621,894 shares and retaining 3.31 million shares worth approximately $17.5 million. Despite this, institutional investors and hedge funds still collectively own 68.43% of CMPX. Analyst sentiment remains a "Moderate Buy" with an average price target of $12.25, even as the stock trades near its 52-week low.
CMPX|Compass Therapeutics Inc.|Price:1.940|
This article provides a detailed overview of Compass Therapeutics Inc. (CMPX), including its current market trends, real-time quotes, and related analysis. It highlights the company's healthy fundamentals, significant growth potential, and "Buy" ratings from analysts, despite recent stock market underperformance. The company is a clinical-stage oncology-focused biopharmaceutical firm developing antibody-based therapeutics.
CMPX|Compass Therapeutics Inc.|Price:2.092|Chg%:+0.022
This article provides a detailed company profile of Compass Therapeutics, Inc., a clinical-stage oncology biopharmaceutical company. It outlines their proprietary antibody-based therapeutic pipeline, including lead candidate tovecimig and other programs like CTX-471 and CTX-8371, which target various critical biological pathways for anti-tumor responses. The report also includes company information, key executive details, and institutional shareholding data.
Compass Therapeutics Inc. (CMPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Compass Therapeutics Inc. (CMPX), although it states that relevant data for FY2024, FY2025, and its quarters have not yet been disclosed by the company. It briefly touches on regional revenue, noting an unstated amount for the United States, and also mentions business segments.
CMPX|Compass Therapeutics Inc.|Price:2.080|
This article provides a comprehensive stock analysis of Compass Therapeutics Inc. (CMPX), highlighting its healthy fundamentals, significant growth potential, and relatively fair valuation within the Biotechnology & Medical Research industry. It details the company's product pipeline including tovecimig, CTX-471, and CTX-8371, and notes high institutional ownership and a "Buy" rating from analysts with an average target price of $8.50. The analysis also covers various scoring dimensions including financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment, making it suitable for informed investment decisions.
Compass Therapeutics Inc. (CMPX) Financial Health: Profitability & Balance Sheet Analysis
This article analyzes the financial health of Compass Therapeutics Inc. (CMPX), assigning it a current financial score of 6.37, which ranks 259 out of 386 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, but its operating efficiency is low. Key financial metrics related to Cash and cash equivalents, Total assets, Operating profit, Income after tax, and Free cash flow are mentioned, with a note that relevant data have not yet been disclosed by the company for these specific categories.
TradingKey
This article provides a detailed quarterly and annual income statement for Compass Therapeutics Inc. (CMPX). It includes financial data such as total revenue, operating expenses, R&D expenses, operating profit, net non-operating interest income, income before tax, income after tax, net income, and earnings per share. The piece also offers a FAQ section explaining how to read an income statement and defining key financial terms.
TradingKey
This article provides a detailed cash flow statement for Compass Therapeutics Inc. (CMPX), presenting quarterly and annual data for operating, investing, and financing activities. It also includes an FAQ section explaining key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free cash flow, with specific figures for CMPX. The data helps evaluate the company's financial health, illustrating how it generates and uses cash from its various business functions.
Compass Therapeutics, Inc. Revenue Breakdown – NASDAQ:CMPX
This article provides a revenue breakdown for Compass Therapeutics, Inc. (NASDAQ: CMPX) on the TradingView platform. It highlights that the market was closed with no trades at the time of publication and offers financial data, news, community interaction, and technical analysis tools for the company.
Compass Therapeutics Inc. (CMPX) Institutional Confidence
Compass Therapeutics Inc. (CMPX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional investors hold 90.26% of outstanding shares, a 28.41% increase quarter-over-quarter. The largest institutional shareholder is Bill Nygren | OAKMX, although their holdings decreased by 77.39%.
Compass Therapeutics (CMPX) Jefferies Global Healthcare Conference 2026 Summary
This article summarizes Compass Therapeutics' presentation at the Jefferies Global Healthcare Conference 2026, highlighting key clinical results and upcoming regulatory milestones. Their lead asset, tovecimig, showed significant efficacy in biliary tract cancer, with an FDA meeting scheduled for early to mid-August and a rolling Biologics License Application submission planned for later this year. The company also provided updates on its pipeline, including a next-generation CD137 agonist and two bispecific antibodies, with multiple data readouts anticipated in the second half of the year.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that data for its drug, tovecimig, will be presented as an oral Proffered Paper at the European Society for Medical Oncology (ESMO) Congress in October 2026. The presentation will detail results from the randomized, controlled Phase 2/3 COMPANION-002 clinical trial, which evaluated tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer. The abstract and presentation highlight the company's progress in developing proprietary antibody-based therapeutics for oncology.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that its Tovecimig data, specifically from the randomized clinical trial COMPANION-002, has been accepted for an oral presentation at the ESMO Congress 2026. The presentation will detail results from its Phase 2/3 trial assessing tovecimig in combination with paclitaxel for patients with advanced biliary tract cancer. The presentation is scheduled for October 24, 2026, during the congress in Madrid, Spain.
Compass Therapeutics to present Phase 2/3 tovecimig trial results at ESMO 2026 in advanced biliary tract cancer
Compass Therapeutics will present Phase 2/3 clinical trial results for its bispecific antibody, tovecimig, combined with paclitaxel, at the ESMO Congress 2026. The presentation will focus on data from the COMPANION-002 trial in advanced biliary tract cancer, led by Dr. Nilofer Azad. This event is expected to highlight Compass's oncology pipeline and advance treatment options for this challenging cancer.
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Compass Therapeutics announced that its abstract featuring data from the COMPANION-002 clinical trial of tovecimig, a bispecific antibody, has been accepted for an oral presentation at the ESMO Congress 2026. The presentation will detail results of the randomized Phase 2/3 trial evaluating tovecimig in combination with paclitaxel for previously treated patients with advanced biliary tract cancer. The congress will be held in Madrid, Spain, from October 23-27, 2026, with the presentation scheduled for October 24.
